TP53 and cancer: Mutations in the tumor suppressor TP53 are more prevalent in colorectal cancers of the TCGA cohort with BRAF and PIK3CA wild type (66.6%) compared with cancers with either or both BRAF and PIK3CA mutated, where mutations in TP53 are encountered in 36.4–46.4% of cases (Fisher’s exact test p < 0.0001, Figure 2A).